Bilenker leaving Lilly’s Loxo; plus updates from Orchard, Genfit, OncXerna, Medable, Neurophth, Elevian, Biofidelity, BIO
Josh Bilenker is leaving Eli Lilly and Co. (NYSE:LLY) as CEO of Loxo Oncology to explore other opportunities, Lilly CSO and SVP Daniel Skovronsky said during the pharma’s 4Q20 earnings conference call. COO Jacob Van Naarden will succeed Bilenker as head of the Lilly unit, which the pharma acquired for $8 billion in January 2019.
Orchard Therapeutics plc (NASDAQ:ORTX) promoted Braden Parker to chief commercial officer from SVP and general manager for North America as the company prepares for the European launch this half of Libmeldy, a gene therapy to treat metachromatic leukodystrophy. Before joining Orchard a year ago, Parker held commercial leadership roles at Celgene Corp., Shire plc’s NPS Pharmaceuticals Inc. and, most recently, PTC Therapeutics Inc. (NASDAQ:PTCT), where he led the company’s first U.S. product launch in Duchenne muscular dystrophy and headed strategic planning for the company’s gene therapy unit...